Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study.
Naoki IwamotoShuntaro SatoKaori FurukawaToru MichitsujiKazuteru ShiraishiKounosuke WatanabeKo ChibaMakoto OsakiAtsushi KawakamiPublished in: Modern rheumatology (2024)
Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines.